Navigation Links
Surviving Mesothelioma Puts New Orphan Drug into Perspective in New Article
Date:8/28/2015

The newest therapy to receive orphan drug status for the treatment of malignant pleural mesothelioma will not be available for general use any time soon, according to educational website Surviving Mesothelioma. Click here to read their article on MTG-201.

MTG-201, a biologic therapy that received orphan drug designation for mesothelioma last week from the FDA, will now head into Phase I clinical trials to establish its safety and efficacy in human patients.

“Although MTG-201’s orphan drug designation may help speed its development, it and other orphan drugs must still go through clinical trials before doctors can prescribe them for their mesothelioma patients,” says Surviving Mesothelioma’s Managing Editor, Alex Strauss.

According to the San Francisco-based company that makes MTG-201, the new treatment works by targeting a particular gene defect that can prevent mesothelioma cells from going through the cell death cycle like normal cells. It may also trigger an anti-mesothelioma immune system response.

Orphan drug status, which was established by the Orphan Drug Act of 1983, can be granted to drugs designed to treat diseases effecting fewer than 200,000 people.

To better understand how orphan drug status could impact the development of MTG-201 and how mesothelioma patients can be involved, see Putting the Newest Mesothelioma “Orphan Drug” Into Perspective, now available on the Surviving Mesothelioma website.

Company Press Release, “MTG Biotherapeutics Announces that MTG-201 was Granted Orphan Drug Designation by the US FDA for the Treatment of Malignant Mesothelioma”, August 21, 2015, http://www.prnewswire.com/news-releases/mtg-biotherapeutics-announces-that-mtg-201-was-granted-orphan-drug-designation-by-the-us-fda-for-the-treatment-of-malignant-mesothelioma-300131975.html

For nearly ten years, Surviving Mesothelioma has brought readers the most important and ground-breaking news on the causes, diagnosis and treatment of mesothelioma. All Surviving Mesothelioma news is gathered and reported directly from the peer-reviewed medical literature. Written for patients and their loved ones, Surviving Mesothelioma news helps families make more informed decisions.

Read the full story at http://www.prweb.com/releases/2015/08/prweb12926671.htm.


'/>"/>
Source: PRWeb
Copyright©2015 Vocus, Inc.
All rights reserved

Related medicine news :

1. Scientists Say Enzymes May Influence Chemotherapy Response in Mesothelioma, According to Surviving Mesothelioma
2. New Research Unveils Potential Method for Improved Response to Mesothelioma Drug, According to Surviving Mesothelioma
3. Survey Finds Some Physicians Inadequately Trained to Diagnose and Manage Mesothelioma, According to Surviving Mesothelioma
4. New Study Quantifies Mesothelioma Risk After Closure of Asbestos Industry, According to Surviving Mesothelioma
5. New Trial Will Test Virus-Delivered Treatment for Mesothelioma, According to Surviving Mesothelioma
6. Mesothelioma Growth in Mice Slowed by Kidney Drug in New Study, According to Surviving Mesothelioma
7. New Report Focuses on the Complex Process of Mesothelioma Diagnosis, According to Surviving Mesothelioma
8. New Mesothelioma Treatment Guidelines Issued By European Researchers, According to Surviving Mesothelioma
9. New Research Reveals Some Patients Experience Extended Mesothelioma Survival with Repeat Treatment, According to Surviving Mesothelioma
10. Scientists Link Protein Marker with Mesothelioma Prognosis in New Study, According to Surviving Mesothelioma
11. Study Finds Mesothelioma Behaves Differently in Younger People, According to Surviving Mesothelioma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/12/2019)... ... ... AI for preventable harm analytics leader Jvion today announced that Jvion was ... Potential of AI”, which provides a “tip of the spear” analysis of the healthcare ... clients to complete a full KLAS analysis, Jvion was featured as having “by far ...
(Date:11/12/2019)... ... 12, 2019 , ... Raintree Rehab, a division of Raintree ... rehabilitation operators throughout the United States and Physitrack, an Apple Mobility Partner and ... a joint venture to develop and market clinical outcomes data solutions. , Both ...
(Date:11/11/2019)... Calif. (PRWEB) , ... November 11, 2019 , ... ... of business support services to dental groups in the United States, today announced ... the community of Lodi, CA. , Patients will enjoy convenient hours, comfortable offices ...
(Date:11/11/2019)... YORK (PRWEB) , ... November 11, 2019 , ... ... (CMP), today called for improved foodborne illness prevention and urges increased adoption of ... for a series of vegetable products sold to select retailers in the ...
(Date:11/9/2019)... ... 08, 2019 , ... Pennsylvania College of Health Sciences, the ... after the fourth quarter of the 2018-2019 academic year, the school’s NCLEX scores ... The College’s annual pass rate for the 2018-2019 academic year was 95.02%, maintaining ...
Breaking Medicine News(10 mins):
(Date:11/6/2019)... ... ... James M. Barthel, CEO of MT2 Firing Range Services said, “MT2 gives shooting ... profit by giving the range owner/manager the highest value for their reclaimed lead. ... for their lead. No one reclaims more lead or pays more for their lead ...
(Date:11/6/2019)... ... November 06, 2019 , ... ... presented Northern Westchester Hospital (NWH) President and CEO, Joel Seligman, with the Make ... for his commitment to raising awareness, providing education and registering lifesaving donors. Assemblyman ...
(Date:11/5/2019)... N.J. (PRWEB) , ... November 05, 2019 , ... ... Antonio, 555 South Alamo Street in Texas will be a timely program providing ... in the management of chronic pain. , The Texas Medical Board requires all ...
Breaking Medicine Technology: